Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines.

RNA 52

RNA Genome Genomics DNA 52

pharmaphorum

JANUARY 26, 2023

The combination of advanced long- and short-read genomic sequencing technologies holds great promise for precision oncology, and in the development of mRNA vaccines for certain cancers. Just one mutation can lead to a complete change in protein formation. Just one mutation can lead to a complete change in protein formation.

Genome 125

Genome Genomics Genome Project Genetics 125

Drug Discovery World

JULY 17, 2024

The findings, published in Nature , offer the first step in longed-for hope for the development of a treatment in the future. While nearly all genes known to be involved in NDD are responsible for making proteins, RNU4-2 is not; instead, it makes an RNA molecule that plays an important role in how other genes are processed in cells.

Genetics 52

Genetics Genome Project Genome Genomics 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. billion in funding.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Roots Analysis

AUGUST 28, 2022

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. 70+ spatial Genomics solutions are developed by industry and non-industry players. Concluding Remarks.

Genome 52

Genome Genomics RNA Genome Project 52

Drug Discovery World

OCTOBER 6, 2022

In pursuit of this, the number of new therapeutics in development has boomed. New classes of therapies have added to this growth, including immune checkpoint inhibitors and genome targeted therapies. Both the binary and quantitative have relied on measurement of protein, DNA, and more recently, RNA.

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52